Thomas N Kakuda (T N Kakuda)

ORCID

Publication Activity (10 Years)

Years Active: 2014-2023
Publications (10 Years): 8

Top Venues

Journal of clinical pharmacology

Antiviral therapy

HIV medicine

Hepatology (Baltimore, Md.)

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas N Kakuda, Atef Halabi, Gernot Klein, Madhu Sanga, Carine Guinard-Azadian, Monika Kowalik, Katja Nedoschinsky, Julius Nangosyah, Emmanuel Njumbe Ediage, Vera Hillewaert, Peter Verboven, Ivo Goris, Jan Snoeys, Martyn Palmer, Michael Biermer
Pharmacokinetics of Jnj-73763989 And Jnj-56136379 (Bersacapavir) In Participants With Moderate Hepatic Impairment. Journal of clinical pharmacology (2023)
Thomas N Kakuda, Atef Halabi, Gernot Klein, Madhu Sanga, Carine Guinard-Azadian, Monika Kowalik, Katja Nedoschinsky, Julius Nangosyah, Emmanuel Njumbe Ediage, Vera Hillewaert, Peter Verboven, Ivo Goris, Jan Snoeys, Martyn Palmer, Michael Biermer
Pharmacokinetics of JNJ-73763989 and JNJ-56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment. Journal of clinical pharmacology (2023)
Edward J Gane, Man-Fung Yuen, Thomas N Kakuda, Tetsuro Ogawa, Yasushi Takahashi, Nele Goeyvaerts, Isabelle Lonjon-Domanec, Tamisha Vaughan, Thomas Schluep, James Hamilton, Emmanuel Njumbe Ediage, Vera Hillewaert, Jan Snoeys, Oliver Lenz, Willem Talloen, Michael Biermer
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B. Antiviral therapy 27 (3) (2022)
Thomas N Kakuda, Jeysen Z Yogaratnam, Christopher Westland, Edward J Gane, Christian Schwabe, Jennifer Vuong, Megha Patel, Jan Snoeys, Willem Talloen, Oliver Lenz, John Fry, Sushmita Chanda, Pieter Van Remoortere
Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers. Antiviral therapy 26 (1-2) (2021)
Edward J Gane, Catherine A Stedman, Christian Schwabe, Leen Vijgen, Sushmita Chanda, Thomas N Kakuda, John Fry, Lawrence M Blatt, Matthew W McClure
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis. Hepatology (Baltimore, Md.) 68 (6) (2018)
Thomas N Kakuda, Matthew W McClure, Christopher Westland, Jennifer Vuong, Marie-Claude Homery, Gwendoline Poizat, Laure Viguerie, Caroline Denot, Alain Patat, Qingling Zhang, James Hui, David Apelian, David B Smith, Sushmita M Chanda, John Fry
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects. Pharmacology research & perspectives 6 (3) (2018)
Sofie Deleu, Thomas N Kakuda, Kurt Spittaels, Jurgen J Vercauteren, Vera Hillewaert, Amy Lwin, Lorant Leopold, Richard M W Hoetelmans
Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healthy volunteers. British journal of clinical pharmacology 84 (11) (2018)
H M Crauwels, Thomas N Kakuda, B Ryan, C Zorrilla, O O Osiyemi, S Yasin, K Brown, P Verboven, V Hillewaert, B Baugh
Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women. HIV medicine 17 (9) (2016)
Thomas N Kakuda, Vanitha Sekar, Ludo Lavreys, Els De Paepe, Tanja Stevens, Marc Vanstockem, Tony Vangeneugden, Richard M W Hoetelmans
Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food. Clinical pharmacology in drug development 3 (5) (2014)

Thomas N Kakuda.css-eqlu8i{font-size:small;padding-left:4px;} (T N Kakuda)

Publication Activity (10 Years)

Top Topics

Top Venues

Thomas N Kakuda (T N Kakuda)